March 2018 Arizona Thoracic Society notes
No abstract available. Article truncated after 150 words. The March 2018 Arizona Thoracic Society meeting was held on Wednesday, March 28, 2018 at the HonorHealth Rehabilitation Hospital beginning at 6:30 PM. This was a dinner meeting with case presentations. There were 12 in attendance representing...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Arizona Thoracic Society
2018-03-01
|
Series: | Southwest Journal of Pulmonary and Critical Care |
Subjects: | |
Online Access: | http://www.swjpcc.com/arizona-ats-notes/2018/3/28/march-2018-arizona-thoracic-society-notes.html |
id |
doaj-ca23de10dd834ed28612014837fed3b0 |
---|---|
record_format |
Article |
spelling |
doaj-ca23de10dd834ed28612014837fed3b02020-11-24T22:04:17ZengArizona Thoracic SocietySouthwest Journal of Pulmonary and Critical Care2160-67732018-03-0116317017110.13175/swjpcc051-18March 2018 Arizona Thoracic Society notesRobbins RA0Phoenix Pulmonary and Critical Care Research and Education Foundation, Gilbert, AZ USANo abstract available. Article truncated after 150 words. The March 2018 Arizona Thoracic Society meeting was held on Wednesday, March 28, 2018 at the HonorHealth Rehabilitation Hospital beginning at 6:30 PM. This was a dinner meeting with case presentations. There were 12 in attendance representing the pulmonary, critical care, sleep, infectious disease and radiology communities. At the beginning of the meeting several issues were discussed: 1. The Tobacco 21 which had been introduced into the Arizona House was killed in committee by Rep. Jeff Weninger, Chairman of the Commerce Committee. 2. Council of Chapter Representatives (CCR) Meeting and “Hill Day” was cancelled due to inclement weather. It will probably be rescheduled for the summer. An update on pirfenidone in IPF was presented by Jessica Castle, PhD, Medical Science Liaison with Genentech. Dr. Castle discussed the antifibrotic, anti-inflammatory, and anti-oxidant effects of pirfenidone. Data was also presented from post-hoc analysis from pirfenidone trials. • Overall no difference in morality data …http://www.swjpcc.com/arizona-ats-notes/2018/3/28/march-2018-arizona-thoracic-society-notes.htmlYersinia pestisgangrenetobacco 21continuous sympathetic blockadetriad asthmacoronary artery spasmhypersensitivity pneumonitispirfenidoneidiopathic pulmonary fibrosismortality |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Robbins RA |
spellingShingle |
Robbins RA March 2018 Arizona Thoracic Society notes Southwest Journal of Pulmonary and Critical Care Yersinia pestis gangrene tobacco 21 continuous sympathetic blockade triad asthma coronary artery spasm hypersensitivity pneumonitis pirfenidone idiopathic pulmonary fibrosis mortality |
author_facet |
Robbins RA |
author_sort |
Robbins RA |
title |
March 2018 Arizona Thoracic Society notes |
title_short |
March 2018 Arizona Thoracic Society notes |
title_full |
March 2018 Arizona Thoracic Society notes |
title_fullStr |
March 2018 Arizona Thoracic Society notes |
title_full_unstemmed |
March 2018 Arizona Thoracic Society notes |
title_sort |
march 2018 arizona thoracic society notes |
publisher |
Arizona Thoracic Society |
series |
Southwest Journal of Pulmonary and Critical Care |
issn |
2160-6773 |
publishDate |
2018-03-01 |
description |
No abstract available. Article truncated after 150 words. The March 2018 Arizona Thoracic Society meeting was held on Wednesday, March 28, 2018 at the HonorHealth Rehabilitation Hospital beginning at 6:30 PM. This was a dinner meeting with case presentations. There were 12 in attendance representing the pulmonary, critical care, sleep, infectious disease and radiology communities.
At the beginning of the meeting several issues were discussed:
1. The Tobacco 21 which had been introduced into the Arizona House was killed in committee by Rep. Jeff Weninger, Chairman of the Commerce Committee.
2. Council of Chapter Representatives (CCR) Meeting and “Hill Day” was cancelled due to inclement weather. It will probably be rescheduled for the summer.
An update on pirfenidone in IPF was presented by Jessica Castle, PhD, Medical Science Liaison with Genentech. Dr. Castle discussed the antifibrotic, anti-inflammatory, and anti-oxidant effects of pirfenidone.
Data was also presented from post-hoc analysis from pirfenidone trials.
• Overall no difference in morality data … |
topic |
Yersinia pestis gangrene tobacco 21 continuous sympathetic blockade triad asthma coronary artery spasm hypersensitivity pneumonitis pirfenidone idiopathic pulmonary fibrosis mortality |
url |
http://www.swjpcc.com/arizona-ats-notes/2018/3/28/march-2018-arizona-thoracic-society-notes.html |
work_keys_str_mv |
AT robbinsra march2018arizonathoracicsocietynotes |
_version_ |
1725829687370842112 |